Bladder Cancer and Urothelial Cancer Clinical Trials

Norton Cancer Institute is at the forefront of cancer treatment research. As principal investigators on numerous trials, our specialist physicians have access to innovative treatments and numerous bladder cancer clinical trials.

Learn more about participating in a clinical trial at Norton Healthcare.

Active bladder cancer and urothelial cancer clinical trials include:

Bladder Cancer

A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

Muscle Invasive Bladder Cancer (MIBC)

A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder […]

Urothelial Bladder Cancer

A Phase 2, Multicenter, Single-Arm Trial of CV301 in Combination with PD-1/L1 Blockade in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer

Urothelial Cancer

Retrospective Observational Study to Assess the Efficacy of Anti-PD-(L)1 Treatment in Subjects with Fibroblast Growth Factor Receptor Aberrations

Urothelial Cancer

A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with Selected FGFR Gene Alterations

Urothelial Cancer

A Phase III, Randomized, Open Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care […]

Urothelial Cancer

A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer after Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy

Urothelial Carcinoma

A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI?PD-L1 ANTIBODY) IN COMBINATION WITH GEMCITABINE/CARBOPLATIN VERSUS GEMCITABINE/CARBOPLATIN ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ARE INELIGIBLE FOR CISPLATIN-BASED THERAPY

Urothelial Carcinoma

A Phase Ib/II Open Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Locally Advanced Or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy (MORPHEUS-mUC)

Urothelial Carcinoma

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma

Cancer – 4673

Appointments

Cancer care that isn’t too far from home.

(502) 629-HOPE (4673)


Request an Appointment Online

Clinical trials

Clinical Trials

Learn more about clinical trials at Norton Healthcare
(502) 629-3501

Cokie Roberts’ 17-year breast cancer survival points to medical advances

When television journalist Cokie Roberts was diagnosed with breast cancer in 2002, she had reason to be optimistic. The 15-year survival rate for breast cancer patients was about 70%, meaning the odds were with her, […]

Read Full Story

Using vaccines to treat brain cancer: 4 things to know about this immunotherapy trial

Immunotherapy is a method of treating cancer, and new immune treatments are being studied across the country. Norton Cancer Institute is participating in a clinical trial conducted by AIVITA Biomedical Inc. to study whether a […]

Read Full Story

Why do I ride in Bike to Beat Cancer? Because I miss you, Rhonda

Ever have that work friend that turns into a real friend? Rhonda Hoffman was that real friend. We met not long after I moved here from Cincinnati for a career change. After several years, we […]

Read Full Story

Thomas M. Woodcock, M.D., to retire; pioneered cancer care in Louisville and Southern Indiana

Thomas M. Woodcock, M.D., came to Louisville in 1981 and was one of four founders of what is now Norton Cancer Institute. After almost 40 years as a medical oncologist, Dr. Woodcock plans to retire […]

Read Full Story

New dad gets ependymoma brain tumor diagnosis one day after son’s birth

March 2016 was a life-changing time for the Davis family. On March 23, Matt Davis and his wife, Hailey, celebrated the birth of their son, Finley. The next day, Matt learned he had a rare […]

Read Full Story
Related Stories

Cokie Roberts’ 17-year breast cancer survival points to medical advances

When television journalist Cokie Roberts was diagnosed with breast cancer in 2002, she had reason to be optimistic. The 15-year survival rate for breast cancer patients was about 70%, meaning the odds were with her, […]

Read Full Story

Using vaccines to treat brain cancer: 4 things to know about this immunotherapy trial

Immunotherapy is a method of treating cancer, and new immune treatments are being studied across the country. Norton Cancer Institute is participating in a clinical trial conducted by AIVITA Biomedical Inc. to study whether a […]

Read Full Story

Why do I ride in Bike to Beat Cancer? Because I miss you, Rhonda

Ever have that work friend that turns into a real friend? Rhonda Hoffman was that real friend. We met not long after I moved here from Cincinnati for a career change. After several years, we […]

Read Full Story

Thomas M. Woodcock, M.D., to retire; pioneered cancer care in Louisville and Southern Indiana

Thomas M. Woodcock, M.D., came to Louisville in 1981 and was one of four founders of what is now Norton Cancer Institute. After almost 40 years as a medical oncologist, Dr. Woodcock plans to retire […]

Read Full Story

New dad gets ependymoma brain tumor diagnosis one day after son’s birth

March 2016 was a life-changing time for the Davis family. On March 23, Matt Davis and his wife, Hailey, celebrated the birth of their son, Finley. The next day, Matt learned he had a rare […]

Read Full Story

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.